Odyssey Therapeutics

Recent news

• Rating change
  TD Cowen Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating
  Market Newswire · 2026/8/12
• Rating change
  Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)
  TipRanks · 2026/8/6
• Rating change
  Wedbush Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/8/6
• Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Metagenomi, Inc. (MGX) and Autolus Therapeutics (AUTL)
  TipRanks · 2026/8/12
• Rating change
  Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)
  TipRanks · 2026/6/18
• H.C. Wainwright Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $44
  Market Newswire · 2026/9/22
• H.C. Wainwright Initiates Odyssey Therapeutics(ODTX.US) With Buy Rating, Announces Target Price $44
  Market Newswire · 2026/8/27
• J.P. Morgan Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Raises Target Price to $29
  Market Newswire · 2026/8/11
• Rating change
  Oppenheimer Maintains Odyssey Therapeutics(ODTX.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/6/18
• Rating change
  A Quick Look at Today's Ratings for Odyssey Therapeutics(ODTX.US), With a Forecast Between $16.96 to $40
  Market Newswire · 2026/6/3
• H.C. Wainwright Keeps Their Buy Rating on Odyssey Therapeutics, Inc. (ODTX)
  TipRanks · 2026/9/22

Headlines are aggregated automatically and are not independently verified or edited by our team.